Downmodulation of peripheral MOG-specific immunity by pVAXhsp65 treatment during EAE does not reach the CNS

Abstract Most of the therapeutic strategies to control multiple sclerosis are directed to immune modulation and inflammation control. As heat shock proteins are able to induce immunoregulatory T cells, we investigated the therapeutic effect of a genetic vaccine containing the mycobacterial hsp65 gen...

Full description

Saved in:
Bibliographic Details
Published inJournal of neuroimmunology Vol. 268; no. 1; pp. 35 - 42
Main Authors Zorzella-Pezavento, Sofia Fernanda Gonçalves, Chiuso-Minicucci, Fernanda, França, Thais Graziela Donegá, Ishikawa, Larissa Lumi Watanabe, da Rosa, Larissa Camargo, Colavite, Priscila Maria, Marques, Camila, Ikoma, Maura Rosane Valerio, Silva, Célio Lopes, Sartori, Alexandrina
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 15.03.2014
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Most of the therapeutic strategies to control multiple sclerosis are directed to immune modulation and inflammation control. As heat shock proteins are able to induce immunoregulatory T cells, we investigated the therapeutic effect of a genetic vaccine containing the mycobacterial hsp65 gene on experimental autoimmune encephalomyelitis (EAE). Although pVAXhsp65 was immunogenic for mice with EAE and downmodulated specific cytokine induction by MOG, therapy was not able to decrease clinical severity nor to modify immunologic parameters in the CNS. These results indicate that hsp65, administered as a DNA vaccine, was not therapeutic for EAE.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0165-5728
1872-8421
DOI:10.1016/j.jneuroim.2013.12.015